



Supplementary material

## Folic Acid-Appended Hydroxypropyl- $\beta$ -Cyclodextrin Exhibits Potent Antitumor Activity in Chronic Myeloid Leukemia Cells via Autophagic Cell Death


Toshimi Hoshiko, Yasushi Kubota, Risako Onodera, Taishi Higashi, Masako Yokoo, Keiichi Motoyama and Shinya Kimura




**Figure S1.** Expression of folate receptor  $\alpha$  and  $\beta$  in hepatocytes. (a) Folate receptor  $\alpha$  (FR $\alpha$ ) in hepatocytes was measured by flow cytometry using FR $\alpha$ -PE antibody. (b) Folate receptor  $\beta$  (FR $\beta$ ) in hepatocytes was measured by flow cytometry using FR $\beta$ -APC antibody.




**Figure S2.** Effect of HP- $\beta$ -CyDs on caspase 3/7 activity in CML cell lines. (a and b) K562 cells (a) and BV173 cells (b) were incubated with HP- $\beta$ -CyD (1 mM, 5 mM) and FA-HP- $\beta$ -CyD (1 mM, 5 mM) for 48 h, and 10 mM CellEvent™ Caspase-3/7 Green Detection Reagent was added and incubated at 37°C for 30 min. The cells were observed with a fluorescence microscope.




**Figure S3.** Induction of autophagy by FA-M-β-CyD. (a) Detection of autophagy in CML cells. BV173 cells were treated with FA-HP-β-CyD and HP-β-CyD for 2 h. Then, cells were treated with Cyto-ID for 30 min. Cells were observed by fluorescence microscopy. (b) Effect of HP-β-CyDs on LC3B expression in BV173 cells. Cells were treated with FA-HP-β-CyD, HP-β-CyD, imatinib (IM), and rapamycin (Rap) for 2 h. LC3B protein levels were detected by western blotting. (c) The graph shows the fluorescence intensity of bands. \*P < 0.05 compared with control. (d and e) Effects of chloroquine, bafilomycin A1, and LY294002 on the antitumor activity of FA-HP-β-CyD (d) and HP-β-CyD (e) in BV173 cells. \*P < 0.05 compared with FA-HP-β-CyD.




**Figure S4.** Effect of an autophagy inhibitor on FA-HP- $\beta$ -CyD. K562 (a) and BV173 cells (b) were incubated with medium containing FA-HP- $\beta$ -CyD (1 mM, 5 mM) and HP- $\beta$ -CyD (1 mM, 5 mM) in the absence or presence of LY294002 (50  $\mu$ M). Cells were stained with LC3B antibody and observed under a fluorescence microscope.



**Figure S5.** Measurement of intracellular ATP levels and ROS generation in A549 cells. (a) A549 cells were incubated with 1 mM FA-HP- $\beta$ -CyD and 10 mM HP- $\beta$ -CyD for 2 h. Then, the cells were treated with ATP detection reagent. Bar graphs represent the mean  $\pm$  SEM (n=3 per group). (b) A549 cells were incubated with 1 mM FA-HP- $\beta$ -CyD and 10 mM HP- $\beta$ -CyD, and then detected by fluorescence cytometry using ROS detection reagents.



**Figure S6.** Antitumor activity of imatinib and ponatinib. (a) Cell growth inhibitory effect of imatinib in K562 and BV173 cells. IC<sub>50</sub> is shown. (b) Cell growth inhibitory effect of ponatinib in K562 and BV173 cells. IC<sub>50</sub> is shown.



**Figure S7.** Evaluation of the combined effect of HP- $\beta$ -CyD and imatinib on BV173 cells. (a) The combination index (CI) was plotted as a function of the fraction affected (Fa), which represents the percentage of growth inhibition (e.g., 0.5 = 50%). Combinations of multiple equipotent drug concentrations were analyzed for synergistic (CI < 1), additive (CI = 1), or antagonistic (CI > 1) effects. Data are presented as the mean  $\pm$  SD of three independent experiments.




Figure S8. Original western blot figures.